Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy

Molecular and Cellular Biology

Volumn 17, Issue 8, 1997, Pages 4249-4258

  Bontron, Séverine ^a   Ucla, Catherine ^a   Mach, Bernard ^a   Steimle, Viktor ^a,b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; RIBONUCLEASE; TRANSACTIVATOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; DOMINANT GENE; GENE EXPRESSION REGULATION; GENE REPRESSION; HELA CELL; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; RAJI CELL; TRANSACTIVATION;

EID: 0030856452     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.8.4249     Document Type: Article

References (48)

1. Andre, I., A. Gonzalez, B. Wang, J. Katz, C. Benoist, and D. Mathis. 1996. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl. Acad. Sci. USA 93:2260-2263.
2. Attardi, L. D., D. Von Seggern, and R. Tjian. 1993. Ectopic expression of wild-type or a dominant-negative mutant of transcription factor NTF-1 disrupts normal Drosophila development. Proc. Natl. Acad. Sci. USA 90:10563-10567.
3. Barnstable, C. J., W. F. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. Williams, and A. Ziegler. 1978. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens - new tools lor genetic analysis. Cell 14:9-20.
4. Benoist, C., and D. Mathis. 1990. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu. Rev. Immunol. 8:681-715.
5. Bontron, S., V. Steimle, C. Ucla, and B. Mach. 1997. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A. Hum. Genet. 99:541-546.
6. Bowman, T., H. Symonds, L. Gu, C. Yin, M. Oren, and T. Van Dyke. 1996. Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev. 10:826-835.
7. Brent, R., and M. Ptashne. 1985. A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor. Cell 43:729-736.
8. Brown, J. A., X. F. He, S. D. Westerheide, and J. M. Boss. 1996. Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5. Immunogenetics 43:88-91.
9. Calnan, B. J., S. Szychowski, F. K. Chan, D. Cado, and A. Winoto. 1995. A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection. Immunity 3:273-282.
10. Charron, D. J., and H. O. McDevitt. 1979. Analysis of HLA-D regionassociated molecules with monoclonal antibody. Proc. Natl. Acad. Sci. USA 76:6567-6571.
11. De Lerma Barbaro, A., S. Sartoris, G. Tosi, M. Nicolis, and R. S. Accolla. 1994. Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules. J. Immunol. 153:4530-4538.
12. Diedrichs, M., and D. J. Schendel. 1989. Differential surface expression of class II isotypes on activated CD4 and CD8 cells correlates with levels of locus-specific mRNA. J. Immunol. 142:3275-3280.
13. Durand, B., P. Sperisen, P. Emery, E. Barras, M. Zufferey, B. Mach, and W. Reith. 1997. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16:1045-1055.
14. Glimcher, L. H., and C. J. Kara. 1992. Sequences and factors: a guide to MHC class-II transcription. Annu. Rev. Immunol. 10:13-49.
15. Gönczy, P., W. Reith, E. Barras, B. Lisowska-Grospierre, C. Griscelli, M. R. Hadam, and B. Mach. 1989. Inherited immunodeficiency with a defect in a major histocompatibility complex class II promoter-binding protein differs in the chromatin structure of the HLA-DRA gene. Mol. Cell. Biol. 9:296-302.
16. Griscelli, C., B. Lisowska-Grospierre, and B. Mach. 1993. Combined immunodeficiency with defective expression in MHC class II genes, p. 141-154. In F. S. Rosen and M. Seligman (ed.), Immunodeficiencies. Harwood Academic Publishers, Chur, Switzerland.
17. Hachiya, M., A. Chumakov, C. W. Miller, M. Akashi, J. Said, and H. P. Koeffler. 1994. Mutant p53 proteins behave in a dominant, negative fashion in vivo. Anticancer Res. 14:1853-1859.
18. Helbig, H., K. L. Kittredge, A. G. Palestine, M. Coca Prados, and R. B. Nussenblatt. 1991. Gamma-interferon induces differential expression of HLA-DR, -DP and -DQ in human ciliary epithelial cells. Graefes. Arch. Clin. Exp. Ophthalmol. 229:191-194.
19. Herskowitz, I. 1987. Functional inactivation of genes by dominant negative mutations. Nature 329:219-222.
20. Janeway, C. A., K. Bottomly, P. Conrad, S. Conzen, B. Jones, J. Kaye, M. Katz, L. McVay, D. B. Murphy, and J. Tite. 1984. Quantitative variation in Ia antigen expression plays a central role in immune regulation. Immunol. Today 5:55-60.
21. Katz, J. D., B. Wang, K. Haskins, C. Benoist, and D. Mathis. 1993. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74:1089-1100.
22. Kobe, B., and J. Deisenhofer. 1995. Proteins with leucine-rich repeats. Curr. Opin. Struct. Biol. 5:409-416.
23. Lalle, P., C. Moyret Lalle, Q. Wang, J. M. Vialle, C. Navarro, B. Bressac de Paillerets, J. P. Magaud, and M. Ozturk. 1995. Genomic stability and wildtype p53 function of lymphoblastoid colls with germ-line p53 mutation. Oncogene 10:2447-2454.
24. Lloyd, A., N. Yancheva, and B. Wasylyk. 1991. Transformation suppressor activity of a Jun transcription factor lacking its activation domain. Nature 352:635-638.
25. Mach, B., V. Steimle, E. Martinez-Soria, and W. Reith. 1996. Regulation of MHC class II genes: lessons from a disease. Annu. Rev. Immunol. 14:301-331.
26. Maurer, D. H., J. H. Hanke, E. Mickelson, R. R. Rich, and M. S. Pollack. 1987. Differential presentation of HLA-DR, DQ, and DP restriction elements by interferon-gamma-treated dermal fibroblasts. J. Immunol. 139: 715-723.
27. O'Hare, P., and G. Williams. 1992. Structural studies of the acidic transactivation domain of the Vmw65 protein of herpes simplex virus using 1H NMR. Biochemistry 31:4150-4156.
28. Otten, L. A., V. Steimle, S. Bontron, and B. Mach. Unpublished data.
29. Perlmutter, R. M., and J. Alberola-Ila. 1996. The use of dominant-negative mutations to elucidate signal transduction pathways in lymphocytes. Curr. Opin. Immunol. 8:285-290.
30. Platt, J. L. 1996. Xenotransplantation: recent progress and current perspectives. Curr. Opin. Immunol. 8:721-728.
31. Reith, W., S. Satola, C. Herrero Sanchez, I. Amaldi, B. Lisowska-Grospierre, C. Griscelli, M. R. Hadam, and B. Mach. 1988. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein. RF-X. Cell 53:897-906.
32. Reith, W., V. Steimle, and B. Mach. 1995. Molecular defects in the bare lymphocyte syndrome and the regulation of MHC class II genes. Immunol. Today 16:539-546.
33. Riley, J. L., S. D. Westerheide, J. A. Price, J. A. Brown, and J. M. Boss. 1995. Activation of class II MHC genes requires both the X box and the class II transactivator (CIITA). Immunity 2:533-543.
34. Seipel, K., O. Georgiev, and W. Schaffner. 1992. Different activation domains stimulate transcription from remote ('enhancer') and proximal ('promoter') positions. EMBO J. 11:4961-4968.
35. Silacci, P., A. Mottet, V. Steimle, W. Reith, and B. Mach. 1994. Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. J. Exp. Med. 180:1329-1336.
36. Steimle, V., B. Durand, E. Barras, M. Zufferey, M. R. Hadam, B. Mach, and W. Reith. 1995. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1021-1032.
37. Steimle, V., and B. Mach. Unpublished data.
38. Steimle, V., L. A. Otten, M. Zufferey, and B. Mach. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 75:135-146.
39. Steimle, V., C. Siegrist, A. Mottet, B. Lisowska-Grospierre, and B. Mach. 1994. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science 265:106-109.
40. Tabor, S., and C. C. Richardson. 1985. A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes. Proc. Natl. Acad. Sci. USA 82:1074-1078.
41. Takebe, Y., M. Seiki, J. Fujisawa, P. Hoy, K. Yokota, K. Arai, M. Yoshida, and N. Arai. 1988. SRα promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8:466-472.
42. Ucla, C., W. Reith, and B. Mach. Unpublished data.
43. Wang, P., M. Reed, Y. Wang, G. Mayr, J. E. Stenger, M. E. Anderson, J. F. Schwedes, and P. Tegtmeyer. 1994. p53 domains: structure, oligomerization, and transformation. Mol. Cell. Biol. 14:5182-5191.
44. Watson, A. J., F. H. Bach, R. Demars, and I. S. Trowbridge. 1983. Detection of a novel human class II HLA antigen. Nature 304:358-361.
45. Wilkinson, M. 1988. RNA isolation: a mini-prep method. Nucleic Acids Res 16:10933.
46. Yamada, K., D. H. Sachs, and H. DerSimonian. 1995. Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J. Immunol. 155:5249-5256.
47. Zhou, H., and L. H. Glimcher. 1995. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity 2:545-553.
48. Ziegler, A., H.Götz, J. Heinig, C. Muller, F. P. Thinnes, B. Uchanska-Ziegler, and P. Wernet. 1986. Analysis by sequential immunoprecipitations of the specificities of the monoclonal antibodies Tü22, Tü34, Tü35, Tü36, Tü37, Tü39, Tü43, Tü58, and Yd1/63. Hlk directed against human HLA class II antigens. Immunobiology 171:77-92.